Conditions: Dyslipidemia
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 14
Healthy volunteers: yes

Brief summary:
This study will determine definitive bioequivalence of the United States (U.S.) and United Kingdom (UK) formulations of fenofibrate following administration of single doses in healthy adult subjects.

Detailed description:

Arms:
arm 1: Fenofibrate U.S. Formulation arm 2: Fenofibrate UK Formulation

Interventions: intervention 1: fenofibrate (U.S. formulation) intervention 2: fenofibrate (UK formulation)
Intervention descriptions: intervention 1: Single dose of 160 mg fenofibrate U.S. formulation (Tricor®) in one of two treatment periods. intervention 2: Single dose of 160 mg fenofibrate UK formulation (Supralip®) in one of two treatment periods.

Protocol document: